Verdict No. 1904 · Search date 2026-08-01 · Methodology v0.6
Ondansetron,
does it really help with Reduced vomiting during oral rehydration and reduced intravenous-fluid use in pediatric acute gastroenteritis?
30-Second Summary
B
Evidence Grade B · 77 · Safety caution
Single-dose oral ondansetron reduced vomiting and intravenous-fluid use in pediatric gastroenteritis
Diarrhea may increase, and congenital long-QT syndrome, electrolyte abnormalities, or other QT-prolonging drugs require arrhythmia-risk assessment.
What the
research showsThe grade is B. Freedman randomized 215 children, 108 versus 107, while result-table denominators were 107 versus 107; additional vomiting was 15/107 (14%) versus 37/107 (35%), and intravenous fluids were 15/107 (14%) versus 33/107 (31%). Roslund and pooled evidence replicated the effects, giving B with 77 points.
research showsThe grade is B. Freedman randomized 215 children, 108 versus 107, while result-table denominators were 107 versus 107; additional vomiting was 15/107 (14%) versus 37/107 (35%), and intravenous fluids were 15/107 (14%) versus 33/107 (31%). Roslund and pooled evidence replicated the effects, giving B with 77 points.
What the
ads claimOndansetron does not replace fluid; it reduces vomiting so oral rehydration can proceed. Severe dehydration, altered consciousness, bilious vomiting, or severe abdominal pain requires urgent assessment.
ads claimOndansetron does not replace fluid; it reduces vomiting so oral rehydration can proceed. Severe dehydration, altered consciousness, bilious vomiting, or severe abdominal pain requires urgent assessment.
Useful facts when choosing a product
- Ondansetron is a prescription antiemetic that blocks serotonin 5-HT3 receptors.
- Verdict 1882 is B with 77 points and concerns postoperative prevention; this verdict treats pediatric infectious gastroenteritis.
- Pivotal evidence combined weight-based single oral dosing with standardized oral rehydration in emergency care.
Gap Measurement · Verdict 1904 · B 77
What the research actually shows
Freedman randomized 215, but the result table reported 107 participants per group, 214 total. It was an academic trial with GSK support, while the company did not participate in analysis or reporting. Roslund randomized 106 and GSK supplied study medication. Replication exists, but it was not wholly independent of GSK.
Why this is classified as B (77)
Multiple placebo-controlled trials and meta-analysis replicated large reductions in vomiting and intravenous-fluid need, giving B with 77 points.
Counterpoint. Less vomiting does not replace evaluation of cause and dehydration severity, and this is not a verdict for repeated dosing in every child.
Rejudgment record. Cross-check applied — Multiple placebo-controlled randomized trials and meta-analysis consistently reduced vomiting and intravenous-fluid use
Scoring profile behind this grade
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R2 | Independently replicated across trials |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced vomiting during oral rehydration | B | The pivotal primary outcome was 14% versus 35%. |
| Reduced need for intravenous fluids | B | An independent trial and pooled RR of 0.41 replicated the reduction. |
Cross-check — Codex and Claude
This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Double-blind randomized placebo-controlled trial | 107 | Academic trial with partial support from GlaxoSmithKline | Primary endpoint: vomiting during oral rehydration | Additional vomiting 15/107 (14%) versus 37/107 (35%), RR 0.40 (95% CI 0.26 to 0.61); intravenous fluids 15/107 (14%) versus 33/107 (31%). | Pivotal placebo-controlled randomized trial |
| Study 2 | Randomized placebo-controlled trial | 55 | Academic study; GSK supplied study medication | Need for intravenous hydration after failed initial oral rehydration | 11/51 (21.6%) versus 30/55 (54.5%), absolute difference 32.9 points (95% CI 14.54 to 48.37), P<0.001. | Replication trial by a separate investigator group |
| Study 3 | Systematic review and meta-analysis of randomized trials | 1,479 | Independent systematic review | Vomiting cessation, intravenous rehydration, and immediate admission | Vomiting cessation RR 1.44 (95% CI 1.29 to 1.61); intravenous rehydration RR 0.41 (0.29 to 0.59), I-squared 0%. | Synthesis confirming consistency |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-08-01).
Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med. 2006;354:1698-1705. PMID: 16625009. DOI: 10.1056/NEJMoa055119.
checkedRoslund G, Hepps TS, McQuillen KK. The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy. Ann Emerg Med. 2008;52:22-29.e6. PMID: 18006189. DOI: 10.1016/j.annemergmed.2007.09.010.
checkedCarter B, Fedorowicz Z. Antiemetic treatment for acute gastroenteritis in children: an updated Cochrane systematic review. BMJ Open. 2012;2:e000622. DOI: 10.1136/bmjopen-2011-000622.
checkedDraft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-01 · Corrections: none
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-01 · Corrections: none
Cite this verdict
[Chamgap] Ondansetron x less vomiting and intravenous fluid use in pediatric gastroenteritis — Evidence Grade B·77. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/oral-ondansetron-pediatric-gastroenteritis-vomiting-iv-fluids/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.